Ambroxol and bromhexine are expectorants in syrup or tablet form which help make the mucus thinner and therefore easier to be cleared away in patients who . Ambroxol and bromhexine are mainly used by mouth (orally) as expectorants to help make the mucus thinner and therefore easier to be. Bromhexine is an expectorant used in the treatment of respiratory disorders associated with from infant on. Bromhexine is well established and tolerated. Sometimes it is replaced by its metabolite ambroxol, as in Mucosolvan or Mucoangin.
|Genre:||Health and Food|
|Published (Last):||23 October 2005|
|PDF File Size:||11.88 Mb|
|ePub File Size:||10.31 Mb|
|Price:||Free* [*Free Regsitration Required]|
The European Medicines Agency has started a review of medicines containing ambroxol and bromhexine, which are widely used as expectorants medicines that help clear the airwaysas well as to relieve sore throat. Some formulations are used to treat breathing disorders in premature and newborn babies.
bromhexnie This follows concerns over an increased number of reports of allergic reactions, including anaphylactic severe allergic reactions with ambroxol. Medicines containing ambroxol have also been linked to severe skin adverse reactions. In addition, the AFMPS bromhexije concerned about the bromyexine of ambroxol as expectorant in children below 6 years of age and considered that the benefits of these medicines did not outweigh the risks in this population. Since bromhexine gets mainly converted into ambroxol in the body, and there are some reports linking the use of bromhexine with allergic reactions, the AFMPS considered that the review should also cover medicines containing bromhexine.
The European Medicines Agency will now review the available data on the benefits and risks of medicines containing ambroxol and bromhexine, and issue an opinion on the marketing authorisations of these medicines across the European Union EU.
Start of review of ambroxol and bromhexine | European Medicines Agency
Ambroxol and bromhexine are mainly used by mouth as expectorants to help make the mucus thinner and therefore easier to be cleared away in patients with short- or long-term diseases of the lungs or airways. Lozenge formulations are also available to relieve sore throat. Formulations for injection are also used in premature and newborn babies to treat respiratory distress syndrome RDSa condition in which the baby’s lungs are too immature for the baby to breathe properly.
Some of these formulations are also used to increase lung maturation before birth. These medicines have been authorised via national procedures in the following countries: The review is being carried out by the Pharmacovigilance Risk Assessment Committee PRACthe Committee responsible for the evaluation of safety issues for human medicines, which will make a set of recommendations.
The CMDha body representing the EU Member States, is responsible for ensuring harmonised safety standards for medicines authorised via national procedures across the EU. Skip to main content. Human regulatory Overview Research and development Marketing authorisation Post-authorisation Herbal products.
Veterinary regulatory Overview Research and development Marketing authorisation Post-authorisation.
There was a problem providing the content you requested
Start of review of ambroxol and bromhexine. More about the medicine Ambroxol and bromhexine are mainly used by mouth as expectorants to help make the mucus thinner and therefore easier to be cleared away in patients with short- or long-term diseases of the lungs or airways. How useful was this page?
Leave this field blank.